Vertex Pharmaceuticals
VRTX
403 hedge funds and large institutions have $17.1B invested in Vertex Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 157 increasing their positions, 132 reducing their positions, and 37 closing their positions.
81% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 37
72% more call options, than puts
Call options by funds: $361M | Put options by funds: $210M
19% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 132
7% more funds holding
Funds holding: 376 → 403 (+27)
2% less capital invested
Capital invested by funds: $17.4B → $17.1B (-$329M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$306M |
| 2 |
O
OppenheimerFunds
New York
|
+$280M |
| 3 |
State Street
Boston,
Massachusetts
|
+$174M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$109M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$259M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$213M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$172M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$103M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$98.8M |
VRTX Hedge Fund Activity: Q3 2013 in Review
403 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2013, worth a combined $17.1B — down 1.9% from $17.4B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new VRTX positions and 37 closed out — a net gain of 30 holders — while 157 added to existing stakes and 132 trimmed.
The largest buyer was Vanguard Group, adding an estimated $306M. The largest seller was Jennison Associates, cutting an estimated $259M.
- 403 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2013, up from 376 in Q2 2013.
- Funds reported $17.1B of Vertex Pharmaceuticals stock for Q3 2013, down 1.9% quarter-over-quarter.
- 67 funds opened new Vertex Pharmaceuticals positions in Q3 2013 and 37 closed out, a net change of +30 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2013 was Vanguard Group, an estimated $306M added.
- The largest Vertex Pharmaceuticals seller in Q3 2013 was Jennison Associates, an estimated $259M sold.
Based on aggregated 13F filings for Q3 2013.